Ire1 small molecule inhibitors

Abstract

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

1 . A compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof: 
       
         
           
           
               
               
           
         
         wherein, 
       
       
         
           
           
               
               
           
         
       
       is a substituted C 3 -C 10  cycloalkyl that is substituted with 1-3R 1  and 0-3R 2 ;
 each R 1  is independently —OR 6 , —SR 6 , —S(═O)R 7 , —S(═O) 2 R 7 , or —N(R 6 ) 2 ; 
 each R 2  is independently H, halogen, —CN, —OR 8 , —SR 8 , —S(═O)R 9 , —S(═O) 2 R 9 , —S(═O) 2 N(R 8 ) 2 , —NR 8 S(═O) 2 R 9 , —C(═O)R 9 , —OC(═O)R 9 , —CO 2 R 8 , —CO 2 R 9 , —N(R 8 ) 2 , —OC(═O)N(R 8 ) 2 , —NR 8 C(═O)R 9 , —NR 8 C(═O)OR 9 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 each R 6  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, —X-optionally substituted C 1 -C 4 alkyl, —X-optionally substituted C 1 -C 4 heteroalkyl, —X-optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 or two R 6  are taken together with the N atom to which they are attached to form an optionally substituted heterocycle; 
 X is —(C═O)—; 
 each R 7  is independently optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 each R 8  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 or two R 8  are taken together with the N atom to which they are attached to form an optionally substituted heterocycle; 
 each R 9  is independently optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, or optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 A 2  is N or CR A ; 
 R A , R A1 , R A2 , and R A3  are each independently H, halogen, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted aryl, or —OR 10 ; 
 R 10  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 ring A is a monocyclic carbocycle or a monocyclic heterocycle; 
 each R 3  is independently H, halogen, —CN, —OR 11 , —SR 11 , —N(R 11 ) 2 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 each R 11  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 n is 0, 1, 2, 3, or 4; 
 R 4  and R 5  are each independently H, halogen, —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and 
 R 12  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl. 
 
     
     
         2 . (canceled) 
     
     
         3 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein 
       
         
           
           
               
               
           
         
       
       and
 q is 0, 1, 2, or 3. 
 
     
     
         4 . (canceled) 
     
     
         5 . The compound of  claim 3 , or a pharmaceutically acceptable salt, or solvate thereof, wherein 
       
         
           
           
               
               
           
         
       
       and
 q is 0, 1, 2, or 3. 
 
     
     
         6 . (canceled) 
     
     
         7 . The compound of  claim 5 , or a pharmaceutically acceptable salt, or solvate thereof, wherein each R 6  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, —X-optionally substituted C 1 -C 4 alkyl, —X-optionally substituted C 1 -C 4 heteroalkyl, or —X-optionally substituted C 1 -C 4 fluoroalkyl; and each R 2  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, or optionally substituted C 1 -C 4 fluoroalkyl. 
     
     
         8 . The compound of  claim 7 , or a pharmaceutically acceptable salt, or solvate thereof, wherein each R 6  is independently H. 
     
     
         9 . (canceled) 
     
     
         10 . The compound of  claim 5 , or a pharmaceutically acceptable salt, or solvate thereof, wherein 
       
         
           
           
               
               
           
         
         R 6  is H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, —X-optionally substituted C 1 -C 4 alkyl, —X-optionally substituted C 1 -C 4 heteroalkyl, or —X-optionally substituted C 1 -C 4 fluoroalkyl; 
         q is 0 or 1; and 
         R 2  is H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, or optionally substituted C 1 -C 4 fluoroalkyl. 
       
     
     
         11 . The compound of  claim 10 , or a pharmaceutically acceptable salt, or solvate wherein R 6  is optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, —X-optionally substituted C 1 -C 4 alkyl, —X-optionally substituted C 1 -C 4 heteroalkyl, or —X-optionally substituted C 1 -C 4 fluoroalkyl. 
     
     
         12 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein A 2  is N. 
     
     
         13 .- 16 . (canceled) 
     
     
         17 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R A1  is H. 
     
     
         18 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R A2  is H, optionally substituted C 1 -C 4 alkyl, or optionally substituted C 1 -C 4 fluoroalkyl. 
     
     
         19 .- 20 . (canceled) 
     
     
         21 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R A3  is H, halogen, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 fluoroalkyl, or —OR 10 . 
     
     
         22 . The compound of  claim 21 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R A3  is optionally substituted C 1 -C 4 alkyl. 
     
     
         23 .- 26 . (canceled) 
     
     
         27 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein: 
       
         
           
           
               
               
           
         
       
     
     
         28 .- 30 . (canceled) 
     
     
         31 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein: 
       
         
           
           
               
               
           
         
       
     
     
         32 . The compound of  claim 31 , or a pharmaceutically acceptable salt, or solvate thereof, wherein: 
       
         
           
           
               
               
           
         
       
     
     
         33 .- 39 . (canceled) 
     
     
         40 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein each R 3  is independently H, halogen, —CN, —OR 11 , —SR 11 , optionally substituted C 1 -C 4 alkyl, or optionally substituted C 1 -C 4 fluoroalkyl; and n is 1, 2, or 3. 
     
     
         41 . The compound of  claim 40 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R 3  is optionally substituted C 1 -C 4 alkyl. 
     
     
         42 .- 48 . (canceled) 
     
     
         49 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R 4  is halogen or optionally substituted C 1 -C 4 alkyl. 
     
     
         50 .- 57 . (canceled) 
     
     
         58 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R 5  is H. 
     
     
         59 .- 94 . (canceled) 
     
     
         95 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound has the structure of formula (Id) 
       
         
           
           
               
               
           
         
       
       and R A3  is optionally substituted C 1 -C 4  alkyl. 
     
     
         96 . The compound of  claim 95 , or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound has the structure of formula (Ie) 
       
         
           
           
               
               
           
         
       
     
     
         97 . The compound of  claim 95 , or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound has the structure of formula (If) 
       
         
           
           
               
               
           
         
       
     
     
         98 . (canceled) 
     
     
         99 . The compound of  claim 97 , or a pharmaceutically acceptable salt, or solvate thereof, wherein R 4  and R 5  are each independently H, halogen, —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , optionally substituted C 1 -C 4 alkyl, or optionally substituted C 1 -C 4 fluoroalkyl. 
     
     
         100 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound is a compound selected from:
 N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2-chlorobenzenesulfonamide;   N-(5-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-4-methylpyridin-2-yl)-2-chlorobenzenesulfonamide;   N-(5-(2-(((1 r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-4-methylpyridin-2-yl)-2-chlorobenzenesulfonamide;   N-(5-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2-(trifluoromethyl)benzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2-(trifluoromethoxy)benzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2,5-dichlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2-fluorobenzenesulfonamide;   N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl)-3-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-4-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2-methoxybenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-(trifluoromethyl)phenyl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)benzenesulfonamide;   N-(5-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-methylpyridin-2-yl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-chlorophenyl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)phenyl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methoxyphenyl)-2-chlorobenzenesulfonamide;   N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-5-methylpyridin-3-yl)-2-chlorobenzenesulfonamide;   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-2-fluoro-5-methylphenyl)-2-chlorobenzenesulfonamide; or   N-(4-(2-(((1 r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-2,3-dimethylphenyl)-2-chlorobenzenesulfonamide.   
     
     
         101 .- 143 . (canceled) 
     
     
         144 . A pharmaceutical composition comprising: a compound according to  claim 1 , or a pharmaceutically acceptable salt or solvate thereof; and one or more pharmaceutically acceptable excipients. 
     
     
         145 . (canceled) 
     
     
         146 . A method for treating or ameliorating the effects of a disease associated with altered IRE1 signaling, the method comprising administering to a subject in need thereof a pharmaceutical composition, wherein the pharmaceutical composition comprises a compound of  claim 1 . 
     
     
         147 . The method of  claim 146 , wherein the disease is cancer. 
     
     
         148 . (canceled) 
     
     
         149 . The method of  claim 147 , wherein the cancer is ovarian cancer, breast cancer, or triple negative breast cancer (TNBC). 
     
     
         150 .- 154 . (canceled) 
     
     
         155 . The compound of  claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, wherein: 
       
         
           
           
               
               
           
         
       
       and q is 0, 1, 2, or 3;
 each R 6  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 fluoroalkyl, —X-optionally substituted C 1 -C 4 alkyl, —X-optionally substituted C 1 -C 4 heteroalkyl, or —X-optionally substituted C 1 -C 4 fluoroalkyl; 
 each R 2  is independently H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, or optionally substituted C 1 -C 4 fluoroalkyl; 
 A 2  is N; 
 R A1  is H; 
 R A3  is methyl, ethyl, propyl or butyl; 
 R 4  is —Cl, —Br, —F, or —I; 
 R 5  is hydrogen; 
 R A2  is H; 
 ring A is pyridinylene; 
 n is 1, 2, or 3; and 
 R 3  is methyl, ethyl, propyl, or butyl; or 
 R 3  is —OR 11  and R 11  is methyl, ethyl, propyl, or butyl; or 
 R 3  is —OR 11  and R 11  is CF 3  or —CH 2 CF 3 .